Mesa Laboratories MLAB Business Segments
| FY'26 | FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|---|
| Revenue by Business | |||||
| Biopharmaceutical Development | $48.63M-0.2% | $48.73M+19.7% | $40.71M-14.0% | $47.37M+3.9% | |
| Clinical Genomics | $45.39M-3.6% | $47.08M-10.5% | $52.59M-15.6% | $62.3M+89.7% | |
| Gross Profit by Business | |||||
| Biopharmaceutical Development | $28.55M-4.5% | $29.91M+17.8% | $25.4M-16.3% | $30.34M+6.1% | |
| Clinical Genomics | $26.03M+1.4% | $25.67M-5.2% | $27.08M-16.6% | $32.49M+172% | |
| Cost Of Revenue by Business | |||||
| Biopharmaceutical Development | $20.07M+6.7% | $18.82M+22.9% | $15.31M— | —— | |
| Clinical Genomics | $19.36M-9.6% | $21.41M-16.1% | $25.51M— | —— | |
| Cost Of Revenue Other by Business | |||||
| Biopharmaceutical Development | $18.25M+6.0% | $17.22M+25.2% | $13.75M— | —— | |
| Clinical Genomics | $18.02M-9.8% | $19.97M-0.8% | $20.13M— | —— | |
| Inventory Net by Business | |||||
| Biopharmaceutical Development | $24.06M— | —— | $31.92M+21.1% | $26.36M— | |
| Clinical Genomics | $36.18M— | —— | $48.42M-10.2% | $53.89M— | |
| Cost Of Goods And Services Sold Depreciation by Business | |||||
| Biopharmaceutical Development | $308K+37.5% | $224K0.0% | $224K— | —— | |
| Clinical Genomics | $578K-15.0% | $680K-27.4% | $937K— | —— | |
| Goodwill by Business | |||||
| Biopharmaceutical Development | $200.43M— | —— | $295.63M-9.0% | $324.72M— | |
| Clinical Genomics | $68.39M— | —— | $211.6M-61.0% | $543.21M— | |
| Cost Of Goods And Services Sold Amortization by Business | |||||
| Biopharmaceutical Development | $1.51M+10.1% | $1.37M+2.6% | $1.34M— | —— | |
| Clinical Genomics | $765K0.0% | $765K-82.8% | $4.45M— | —— | |
| Goodwill Foreign Currency Translation Gain Loss by Business | |||||
| Clinical Genomics | $196K+1,733% | -$12K— | —— | $49K— | |
| Revenue by Product | |||||
| Service | $45.74M+7.4% | $42.58M+8.1% | $39.39M+1.9% | $38.65M+10.7% | |
| Revenue by Geography | |||||
| CN | $20.45M-19.2% | $25.31M+1.5% | $24.93M-3.3% | $25.8M+56.2% | |
| Other | $111.79M+12.9% | $99.05M+16.7% | $84.86M+11.7% | $76M+10.5% | |
| US | $116.9M+0.2% | $116.62M+9.6% | $106.4M-9.3% | $117.28M+18.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Mesa Laboratories break its business down?
- Mesa Laboratories (MLAB) reports revenue by business across 3 parts — Biopharmaceutical Development, Calibration Solutions and Clinical Genomics. Each is extracted from the segment footnotes and tracked over time.
- Where does Mesa Laboratories's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Mesa Laboratories's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
